{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:35:37Z","timestamp":1780612537182,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03763-2","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T19:02:11Z","timestamp":1693249331000},"page":"3119-3128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-8569","authenticated-orcid":false,"given":"Simone","family":"Morra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia Luca","family":"Piccinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cano Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tappero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reha-Baris","family":"Incesu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Scheipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Colla\u2019 Ruvolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"de Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Terrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Ahyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Carmignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"crossref","unstructured":"Stephenson A, Eggener SE, Bass EB et al (2019) Diagnosis and treatment of early stage testicular cancer guideline: AUA GUIDELINE","DOI":"10.1097\/JU.0000000000000318"},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours. Eur Urol 70:93\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.029","journal-title":"Eur Urol"},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-018-0029-0","volume":"4","author":"L Cheng","year":"2018","unstructured":"Cheng L, Albers P, Berney DM et al (2018) Testicular cancer. Nat Rev Dis Primer 4:29. https:\/\/doi.org\/10.1038\/s41572-018-0029-0","journal-title":"Nat Rev Dis Primer"},{"key":"3763_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070499","author":"M Chovanec","year":"2022","unstructured":"Chovanec M, Cheng L (2022) Advances in diagnosis and treatment of testicular cancer. BMJ. https:\/\/doi.org\/10.1136\/bmj-2022-070499","journal-title":"BMJ"},{"key":"3763_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.20.03296","volume":"39","author":"S Gillessen","year":"2021","unstructured":"Gillessen S, Sauv\u00e9 N, Collette L et al (2021) Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): Results from the IGCCCG Update Consortium. J Clin Oncol 39:1563\u20131574. https:\/\/doi.org\/10.1200\/JCO.20.03296","journal-title":"J Clin Oncol"},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.20.03292","volume":"39","author":"J Beyer","year":"2021","unstructured":"Beyer J, Collette L, Sauv\u00e9 N et al (2021) Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol 39:1553\u20131562. https:\/\/doi.org\/10.1200\/JCO.20.03292","journal-title":"J Clin Oncol"},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"e12390","DOI":"10.1097\/MD.0000000000012390","volume":"97","author":"JS Park","year":"2018","unstructured":"Park JS, Kim J, Elghiaty A, Ham WS (2018) Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore) 97:e12390. https:\/\/doi.org\/10.1097\/MD.0000000000012390","journal-title":"Medicine (Baltimore)"},{"key":"3763_CR8","unstructured":"Social Security Administration-Actuarial Life Table. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html. Accessed 13 Jan 2023"},{"key":"3763_CR9","unstructured":"SEER Cancer Statistics Review, 1975-2018. In: SEER. https:\/\/seer.cancer.gov\/csr\/1975_2018\/index.html. Accessed 14 Jan 2023"},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.euf.2018.05.006","volume":"5","author":"F Preisser","year":"2019","unstructured":"Preisser F, Bandini M, Mazzone E et al (2019) Validation of the social security administration life tables (2004\u20132014) in localized prostate cancer patients within the surveillance, epidemiology, and end results database. Eur Urol Focus 5:807\u2013814. https:\/\/doi.org\/10.1016\/j.euf.2018.05.006","journal-title":"Eur Urol Focus"},{"key":"3763_CR11","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s11255-022-03221-5","volume":"54","author":"F Chierigo","year":"2022","unstructured":"Chierigo F, Borghesi M, W\u00fcrnschimmel C et al (2022) Life expectancy in metastatic urothelial bladder cancer patients according to race\/ethnicity. Int Urol Nephrol 54:1521\u20131527. https:\/\/doi.org\/10.1007\/s11255-022-03221-5","journal-title":"Int Urol Nephrol"},{"key":"3763_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-022-01257-y","author":"C W\u00fcrnschimmel","year":"2022","unstructured":"W\u00fcrnschimmel C, Nocera L, Wenzel M et al (2022) Race\/ethnicity may be an important predictor of life expectancy in localized prostate cancer patients: novel analyses using social security administration life tables. J Racial Ethn Health Disparities. https:\/\/doi.org\/10.1007\/s40615-022-01257-y","journal-title":"J Racial Ethn Health Disparities"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.euf.2021.02.004","volume":"8","author":"C W\u00fcrnschimmel","year":"2022","unstructured":"W\u00fcrnschimmel C, Coll\u00e0 Ruvolo C, Nocera L et al (2022) Race\/ethnicity determines life expectancy in surgically treated T1aN0M0 renal cell carcinoma patients. Eur Urol Focus 8:191\u2013199. https:\/\/doi.org\/10.1016\/j.euf.2021.02.004","journal-title":"Eur Urol Focus"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s11255-023-03517-0","volume":"55","author":"C Cano Garcia","year":"2023","unstructured":"Cano Garcia C, Piccinelli ML, Tappero S et al (2023) Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities. Int Urol Nephrol 55:1117\u20131123. https:\/\/doi.org\/10.1007\/s11255-023-03517-0","journal-title":"Int Urol Nephrol"},{"key":"3763_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2023.01.003","author":"CC Garcia","year":"2023","unstructured":"Garcia CC, Nimer N, Piccinelli ML et al (2023) Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race\/ethnicity in the United States. Ann Epidemiol. https:\/\/doi.org\/10.1016\/j.annepidem.2023.01.003","journal-title":"Ann Epidemiol"},{"key":"3763_CR16","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/. Accessed 14 Jan 2023"},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"e1026","DOI":"10.1016\/j.clgc.2019.06.003","volume":"17","author":"C Palumbo","year":"2019","unstructured":"Palumbo C, Mistretta FA, Mazzone E et al (2019) Contemporary incidence and mortality rates in patients with testicular germ cell tumors. Clin Genitourin Cancer 17:e1026\u2013e1035. https:\/\/doi.org\/10.1016\/j.clgc.2019.06.003","journal-title":"Clin Genitourin Cancer"},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"22095","DOI":"10.18632\/aging.104063","volume":"12","author":"W Mao","year":"2020","unstructured":"Mao W, Wu J, Kong Q et al (2020) Development and validation of prognostic nomogram for germ cell testicular cancer patients. Aging 12:22095\u201322111. https:\/\/doi.org\/10.18632\/aging.104063","journal-title":"Aging"},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.euo.2018.04.005","volume":"1","author":"SL Woldu","year":"2018","unstructured":"Woldu SL, Moore JA, Ci B et al (2018) Practice patterns and impact of postchemotherapy retroperitoneal lymph node dissection on testicular cancer outcomes. Eur Urol Oncol 1:242\u2013251. https:\/\/doi.org\/10.1016\/j.euo.2018.04.005","journal-title":"Eur Urol Oncol"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/2090598X.2022.2084902","volume":"20","author":"YA Noureldin","year":"2022","unstructured":"Noureldin YA, Alqirnas MQ, Aljarallah MF et al (2022) Testicular cancer among Saudi adults: hands on a nationwide cancer registry over 10 years. Arab J Urol 20:182\u2013188. https:\/\/doi.org\/10.1080\/2090598X.2022.2084902","journal-title":"Arab J Urol"},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1620\/tjem.252.219","volume":"252","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Koyama J, Goto T et al (2020) Trends in age and histology of testicular cancer from 1980\u20132019: a single-center study. Tohoku J Exp Med 252:219\u2013224. https:\/\/doi.org\/10.1620\/tjem.252.219","journal-title":"Tohoku J Exp Med"},{"key":"3763_CR22","first-page":"3885","volume":"23","author":"G Facchini","year":"2019","unstructured":"Facchini G, Rossetti S, Berretta M et al (2019) Prognostic and predictive factors in testicular cancer. Eur Rev Med Pharmacol Sci 23:3885\u20133891","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/medicina59030451","volume":"59","author":"C Cano Garcia","year":"2023","unstructured":"Cano Garcia C, Panunzio A, Tappero S et al (2023) Survival of testicular pure embryonal carcinoma vs. mixed germ cell tumor patients across all stages. Medicina (Mex) 59:451. https:\/\/doi.org\/10.3390\/medicina59030451","journal-title":"Medicina (Mex)"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/cancers15030694","volume":"15","author":"C Cano Garcia","year":"2023","unstructured":"Cano Garcia C, Barletta F, Incesu R-B et al (2023) Survival of testicular pure teratoma vs. mixed germ cell tumor patients in primary tumor specimens across all stages. Cancers 15:694. https:\/\/doi.org\/10.3390\/cancers15030694","journal-title":"Cancers"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03763-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:21:24Z","timestamp":1698412884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03763-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03763-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shahrokh F. Shariat: Horonraria: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Consulting or Advisory Role: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Speakers\u2019 Bureau: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen, Movember Foundation. Patents: Method to determine prognosis after therapy for prostate cancer - granted 2002-09-06, Methods to determine prognosis after therapy for bladder cancer - granted 2003-06-19, Prognostic methods for patients with prostatic disease - granted 2004-08-05; Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma - granted 2010-07-20. Our research was conducted without any other potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All analyses and their reporting followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study\u2010 specific Institutional Review Board ethics approval as not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}